CRISPR's next act: the companies editing the epigenome to treat disease
Reported byNature News ↗·Sourced by Goodlede
Multiple companies are advancing epigenome-editing therapies using CRISPR technology to treat diseases by modifying gene expression without altering DNA sequence itself, representing a significant expansion of CRISPR's therapeutic potential beyond direct genetic cuts.
Early-stage therapeutic applications; regulatory approval and human efficacy remain to be demonstrated.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at Nature News
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede
Health
Magic Mushroom Compound Could Offer a New Approach to Treating Chronic Tinnitus
ScienceAlert · Caution
Health
Laurentian University sports psychology professor completes marathon after long COVID diagnosis
CBC News · Verified
Science
Telling one guiña from another: It's all about the angle
Mongabay · Verified